Compare CRSP & XMTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRSP | XMTR |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.2B |
| IPO Year | 2016 | 2021 |
| Metric | CRSP | XMTR |
|---|---|---|
| Price | $50.21 | $88.37 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 10 |
| Target Price | ★ $70.29 | $58.60 |
| AVG Volume (30 Days) | ★ 1.7M | 851.5K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.95 |
| EPS | N/A | ★ N/A |
| Revenue | $289,590,000.00 | ★ $686,631,000.00 |
| Revenue This Year | $807.72 | $23.76 |
| Revenue Next Year | $172.52 | $18.38 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 9169.85 | 25.87 |
| 52 Week Low | $35.38 | $29.60 |
| 52 Week High | $78.48 | $93.13 |
| Indicator | CRSP | XMTR |
|---|---|---|
| Relative Strength Index (RSI) | 46.50 | 73.03 |
| Support Level | $44.82 | $41.85 |
| Resistance Level | $60.45 | N/A |
| Average True Range (ATR) | 2.49 | 5.38 |
| MACD | -0.37 | 0.92 |
| Stochastic Oscillator | 35.44 | 88.34 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Xometry Inc is engaged in providing AI-enabled manufacturing equipment. Its buyers include engineers, product designers, procurement and supply chain personnel, inventors, and business owners. The manufacturing processes offered by the company include CNC Machining, Injection Molding, Urethane Casting, 3D Printing, and Die Casting. The company is organized into two segments referred to as the U.S. and the International. The majority of its revenue is derived from the U.S. segment.